Semaglutide is FDA-approved for long-term or chronic weight management in obese patients with a body mass index (BMI) of 30 or greater or overweight patients with a BMI of 27 or greater with at least one weight-related condition such as type 2 diabetes, high blood pressure, high cholesterol, or others
Orthodontic procedures in the treatment of congenital cleft palate
Here's what actually keeps a GLP-1 patient on program for 6 to 12 months: A structured check-in cadence, not "see you next month" Weigh-in and measurement touchpoints that create accountability between visits Automated encouragement timed to hit right before the typical plateau Proactive outreach before a patient's usual drop-off window, not after they've gone quiet Flexible, one-tap rebooking instead of a phone call nobody has time to make None of this is about better medicine
With proper documentation of medical necessity, insurers often cover the cost of oral semaglutide for weight loss
Tirzepatide's added GIP activity appears to further enhance fat metabolism and reduce food intake, which is the leading theory for why it tends to outperform semaglutide on weight loss
In this dynamic and rapidly evolving landscape, continued innovation, strategic investments, and collaboration across the pharmaceutical industry will be key to unlocking the full potential of GLP-1 receptor agonists